MenaQ7 vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical companies
NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7 vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil.
“Dois” is “Two” in Portugese, and “ka” signifies “K.”
Biolab Farmacêutica is one of the largest pharmaceutical companies in Brazil, and the number one pharmaceutical company for cardiology prescriptions.
More than 600 cardiologists attended the event hosted by Biolab, and NattoPharma, world leaders in vitamin K2 research and development, had representatives on hand to explain the substantial body of science supporting MenaQ7 vitamin K2 as MK-7, specifically the cardiovascular benefits.
“It was our pleasure to participate in the Brazilian launch of Doiska MenaQ7, and a privilege to present our clinical substantiation to more than 600 engaged cardiologists in São Paulo,” says Dr Hogne Vik, NattoPharma Chief Medical Officer, who presented alongside respected cardiologist Prof. Dr Francisco Fonseca.
According with Flavio Zemella, Biolab Marketing Director, the symposium was very successful and physicians are anxious about Doiska MenaQ7 arrival in the pharmacies, expected by beginning of August this year.
“We are confident the partnership between NattoPharma and Biolab will be very fruitful as we foresee the product will benefit thousands of Brazilians across the country.”